Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1
- PMID: 7705708
- DOI: 10.1006/gyno.1995.1104
Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1
Abstract
Mutations of the p53 gene often result in the overexpression of p53 protein. Previous studies have suggested that the function of p53 and its mutant protein forms may be linked with the disease course of patients with a breast carcinoma. In the present study, we tested 462 primary breast carcinomas for the presence of p53 antigen using immunohistochemical methods employing antibodies against the clone, DO-1. These tumors were also immunohistochemically stained using the monoclonal antibody, MIB-1, in order to demonstrate the presence of Ki67. Comparison of the presence of p53 with other prognostic parameters revealed highly significant negative correlations with estrogen- and progesterone-receptor status (P < 0.001 and P = 0.001, respectively) as well as positive correlations with both the presence of MIB-1 (P < 0.001) and the histological grading (P = 0.008). The presence of p53 was not correlated with tumor stage and node status. Evaluation of the findings for all 462 tumors as well as for node-positive and -negative subgroups revealed less favorable findings for overall survival and the disease-free period for both p53-positive tumors (for total group, overall survival, P = 0.0002, disease-free period, P = 0.02; for node-positive group, overall survival, P = 0.0004, disease-free period, P = 0.1045) and breast carcinomas with higher proportions of cell nuclei positive for MIB-1 (total, overall survival, P = 0.0026, disease-free period, P = 0.0022; node-positive, overall survival, P = 0.021, disease-free period, P = 0.0882). We were able to demonstrate that p53 expression in breast carcinomas means a significantly worse prognosis for grade II tumors (overall survival, P = 0.0002; disease-free period, P = 0.0116), for overall survival in the case of estrogen-receptor-positive tumors (P = 0.014), and for tumors showing increased proliferation activity (overall survival, P = 0.0477).
Similar articles
-
Mutant p53 expression and DNA analysis in human breast cancer comparison with conventional clinicopathological parameters.Anticancer Res. 1995 Mar-Apr;15(2):581-6. Anticancer Res. 1995. PMID: 7763041
-
Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.Cancer. 2000 Mar 1;88(5):1091-8. Cancer. 2000. PMID: 10699900
-
Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein.Clin Cancer Res. 1996 Jan;2(1):147-54. Clin Cancer Res. 1996. PMID: 9816101
-
[Human mammary carcinoma. A model for the relationship between tumor proliferation, tumor-associate macrophages, and prognostic factors].Veroff Pathol. 1992;138:1-235. Veroff Pathol. 1992. PMID: 1323168 Review. German.
-
Correlation between Ki67 and breast cancer prognosis.Oncology. 2013;84(4):219-25. doi: 10.1159/000346475. Epub 2013 Jan 24. Oncology. 2013. PMID: 23364275 Review.
Cited by
-
AgNOR quantity in needle biopsy specimens of prostatic adenocarcinomas: correlation with proliferation state, Gleason score, clinical stage, and DNA content.Clin Mol Pathol. 1996 Aug;49(4):M209-13. doi: 10.1136/mp.49.4.m209. Clin Mol Pathol. 1996. PMID: 16696076 Free PMC article.
-
Prognostic value of proliferation in invasive breast cancer: a review.J Clin Pathol. 2004 Jul;57(7):675-81. doi: 10.1136/jcp.2003.010777. J Clin Pathol. 2004. PMID: 15220356 Free PMC article. Review.
-
Prognostic significance of immunohistochemical expression of p53 gene product in operable breast cancer.Cancer Res Treat. 2006 Dec;38(4):218-23. doi: 10.4143/crt.2006.38.4.218. Epub 2006 Dec 31. Cancer Res Treat. 2006. PMID: 19771246 Free PMC article.
-
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis.Br J Cancer. 1999 Aug;80(12):1968-73. doi: 10.1038/sj.bjc.6690628. Br J Cancer. 1999. PMID: 10471047 Free PMC article.
-
BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.Br J Cancer. 2008 Feb 12;98(3):571-9. doi: 10.1038/sj.bjc.6604181. Epub 2008 Jan 15. Br J Cancer. 2008. PMID: 18195709 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous